Patents by Inventor Laurent Galibert

Laurent Galibert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Receptor activator of NF-kappaB
    Patent number: 8569456
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: October 29, 2013
    Assignee: Immunex Corporation
    Inventors: Dirk M Anderson, Laurent Galibert, Eugene Maraskovsky
  • Methods and Tools for Screening Agents Exhibiting an Activity on Receptors of the Tumor Necrosis Factor Receptor Superfamily
    Publication number: 20130079246
    Abstract: The present invention provides novel chimeric receptors and methods of screening using the chimeric receptors. The chimeric receptors comprise an extracellular domain of a tumor necrosis factor receptor superfamily (TNFRSF) receptor and an intracellular domain with kinase activity stemming from a receptor tyrosine kinase. According to an embodiment, the chimeric receptor comprises a full-length TNFRSF receptor. The present invention provides means for screening and testing of modulators of TNFRSF receptors.
    Type: Application
    Filed: May 5, 2011
    Publication date: March 28, 2013
    Applicant: ADDEX PHARMA SA
    Inventors: Thibaut De Smedt, Laurent Galibert, Anne-Renee Van Der Vuurst De Vries, Kevin Poupard
  • Chimeric Receptors and Methods for Identifying Agents Exhibiting an Activity on Type 1 Single Pass Transmembrane Receptors
    Publication number: 20130052663
    Abstract: The present invention provides novel chimeric receptors and methods of screening using the chimeric receptors. The chimeric receptors comprise an extracellular domain of a type 1 single pass transmembrane receptor (T1SPTR) and an intracellular domain with kinase activity stemming from a receptor tyrosine kinase. According to an embodiment, the chimeric receptor comprises a full-length T1SPTR. According to another embodiment the chimeric receptor comprises a full-length or truncated tumor necrosis factor receptor (TNFR) or interleukin receptors, or cytokine receptors, or transforming growth factor receptors. The present invention provides means for screening of modulators of TNFRs or interleukin receptors, or cytokine receptors, or transforming growth factor receptors.
    Type: Application
    Filed: May 5, 2011
    Publication date: February 28, 2013
    Applicant: ADDEX PHARMA SA
    Inventors: Thibaut De Smedt, Laurent Galibert, Anne-Renee Van Der Vuurst De Vries, Kevin Poupard
  • RECEPTOR ACTIVATOR OF NF-kappaB
    Publication number: 20120178912
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Application
    Filed: March 19, 2012
    Publication date: July 12, 2012
    Applicant: IMMUNEX CORPORATION
    Inventors: Dirk M. ANDERSON, Laurent GALIBERT, Eugene MARASKOVSKY
  • ANTAGONISTS AND AGONISTS OF LDCAM AND METHODS OF USE
    Publication number: 20080064104
    Abstract: The invention pertains to agonists and antagonists of LDCAM and methods of treating disease and infection by administering one or more LDCAM antagonists or agonists. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: September 7, 2007
    Publication date: March 13, 2008
    Applicant: Amgen Inc.
    Inventors: Laurent Galibert, Wei Yan
  • Methods of inhibiting osteoclastogenesis
    Publication number: 20050089522
    Abstract: Provided here are methods of inhibiting RANKL-induced osteoclastogenesis in patients suffering from specific types of cancer.
    Type: Application
    Filed: November 30, 2004
    Publication date: April 28, 2005
    Applicant: Immunex Corporation
    Inventors: Dirk Anderson, Laurent Galibert
  • Antagonists and agonists of LDCAM and methods of use
    Publication number: 20050058642
    Abstract: The invention pertains to agonists and antagonists of LDCAM and methods of treating disease and infection by administering one or more LDCAM antagonists or agonists. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).
    Type: Application
    Filed: July 23, 2004
    Publication date: March 17, 2005
    Inventors: Laurent Galibert, Wei Yan
  • Receptor activator of NF-kappaB
    Publication number: 20030175840
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Application
    Filed: April 1, 2003
    Publication date: September 18, 2003
    Applicant: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky
  • Receptor activator of NF-&kgr;B
    Patent number: 6537763
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: March 25, 2003
    Assignee: Immunex Corporation
    Inventors: William C. Dougall, Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky
  • Receptor activator of NF-&kgr;B
    Patent number: 6528482
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: March 4, 2003
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky, William C. Dougall
  • Receptor activator of NF-&kgr;B
    Patent number: 6479635
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: November 12, 2002
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky, William C. Dougall
  • Antibodies against ligand for receptor activator of NF-kB
    Publication number: 20020086826
    Abstract: Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to regulate an immune response. The ligands are also useful in screening for inhibitors thereof.
    Type: Application
    Filed: May 25, 2001
    Publication date: July 4, 2002
    Applicant: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky
  • Receptor activator of NF-kappaB
    Publication number: 20020081720
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Application
    Filed: May 31, 2001
    Publication date: June 27, 2002
    Applicant: Immunex Corporation
    Inventors: William C. Dougall, Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky
  • Receptor activator of NF-&kgr;B
    Patent number: 6271349
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: August 7, 2001
    Assignee: Immunex Corporation
    Inventors: William C. Dougall, Laurent Galibert
  • Receptor activator of NF-.kappa.B
    Patent number: 6017729
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: January 25, 2000
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky